High-dose trimethoprim-sulfamethoxazole (TMP-SMX) is known to cause hyperkalemia by blocking amiloride-sensitive sodium (Na) channels in distal nephrons. The purpose of this study was to establish whether the standard dose of TMP-SMX could cause electrolyte disorders.
Introduction
Trimethoprim-sulfamethoxazole (TMP-SMX) is a combination of two antimicrobial agents that act synergistically against a wide variety of bacteria (1) (2) (3) (4) (5) (6) . TMP-SMX is excreted in the urine and 50% of the drug is eliminated in the first 24 hours. Approximately 70% of SMXis protein-bound; it is acetylated (61%) and glucuronide-conjugated (15%) in the liver. In comparison, TMP is excreted into the urine in unchanged form. In non-HIV-infected patients, TMP-SMX is generally well tolerated with adverse reactions occurring in 6-8% of individuals (7, 8) . The most commonadverse reactions involve the gastrointestinal tract (nausea, vomiting) and skin (rash, Stevens-Johnson syndrome, and pruritus) (9).
High-dose TMP-SMX is known to cause hyperkalemia (10). Hyperkalemia arizes through blocking of amiloridesensitive sodium (Na) channels in the collecting duct by TMP, which acts as a potassium (K)-sparing diuretic (ll, 12) . Hyperkalemia is the most common adverse event in HIV-infected patients treated with high doses (13). In addition, standard doses of TMP-SMX can also produce a modest elevation of the plasma K concentration in non-HIVinfected subjects (14, 15). However, few reports have shown that the standard-dose of TMP-SMX can cause hyperkalemia and hyponatremia. In a previous study, we observed a patient who had shown severe hyponatremia and hyperkalemia not only during high-dose TMP-SMX therapy but also during low-dose treatment (Y. Kuroda, manuscript in preparation).
The purpose of this study was to establish whether or not the standard dose of TMP-SMX could cause hyponatremia and hyperkalemia, and whether the dose of TMP-SMX could creatinine (Cr) were measured before and after TMP-SMX therapy in 53 of these patients.
Methods
The medical records of the 53 patients were reviewed. As parameters, the dose of TMP-SMX and the levels of serum Na, K and Cr were analyzed. Laboratory data were obtained just before and on the fifth day (or the nearest) after administration of TMP-SMX. Hyponatremia, hyperkalemia and renal dysfunction were defined as serum Na <135 mEq//, serum K >5.0 mEq// and serum Cr >1.2 mg/dl, respectively.
Statistical Analysis
The unpaired t test was used to comparethe patient age, average dose of TMP, and serum Na, K and Cr concentrations. Renal dysfunction and the incidence of electrolyte disorders were compared using the chi-squared test. Logistic regression analysis was used on the database to examine the association between TMPdose, renal dysfunction, age, sex and electrolyte disorders.
Results
The patient profiles are shown in Table 1 . Most patients had a severe underlying disease such as leukemia, malignant lymphoma or cancer. Many patients were undergoing chemotherapy or steroid therapy, and in most cases TMP-SMX had been prescribed prophylactically to prevent infection.
Electrolyte disorders (hyponatremia and/or hyperkalemia) were seen in 14 of the 53 patients (26.4%). The average dose of TMPwas 145.7±24.9 mg/day. In order to examine the relationship between the incidence of electrolyte disorders and Figure 2 . Changes in serum Na (A), K (B) and Cr (C) concentrations in the three groups before and after treatment with TMP-SMX. Numbers represent serum Na, K and Cr concentrations. Data shownare the mean±SE.
TMPdose, the patients were divided into three groups on the basis of TMP dose: (i) low dose group (TPM <80 mg); (ii) standard dose group (TMP 80-120 mg); and (iii) high dose group (TMP >120 mg). The average dose of TMPwas 68.9± 0.3 mg/day in the low dose group, 82.7±4.7 mg/day in the standard dose group (p<0.0001), and 315.4±72.3 mg/day in the high dose group (p<0.001). There were no statistically significant differences in age, sex, or serum Na, K and Cr concentrations before drug administration between these three groups ( Table 2) . Electrolyte disorders were seen in 9.1% of patients in the low dose group (Fig. 1 SerumNa concentrations did not change significantly after medication in any of the three groups, although there was a tendency for serum Na to decline in the standard dose and high dose groups ( Fig. 2A) . Serum K concentration after TMP-SMXtreatment increased significantly in the high dose group (p=0.017) (Fig. 2B) , as did the serum Cr concentration (p=0.041). In two patients in the standard dose group, a significant decrease in serum Cr concentration was observed. However, these patients had Henoch-Schonlein disease and nephrotic syndrome, and were receiving steroid therapy at the same time as TMP (Fig. 2C) . No statistically significant differences in the incidence of hyperkalemia were noted amongthe other three treatment groups, chemotherapy group, steroid therapy group and other group, indicationg that tumor lysis had no influence on hyperkalemia. Diuretics were prescribed for only one patient and no patients received potassium replacement therapy. electrolyte disorders and renal dysfunction is shown in Table  3 . Electrolyte disorders were seen in 85.7% of patients with These results were compared with other factors by logistic regression analysis (Table 4 ). There were no statistically significant relationships between electrolyte disorders and patient age or sex. The incidence of hyponatremia was increased with the dose of TMPwith an odds ratio of 2.23 (p=0.048), and that of hyperkalemia was increased by the presence of renal dysfunction with an odds ratio of 39.73 (p=0.007). Logistic regression analysis showed that the dose of TMPand the presence of renal dysfunction increased the incidence of electrolyte disorders with an odds ratio of 2.35 (p=0.041) and 80.29 (p=0.003), respectively.
Discussion
High-dose TMP-SMX is known to cause hyperkalemia.
Hyperkalemia is the most commonadverse effect in HIVinfected patients treated with high doses of this drug combination (13). However, standard doses of TMP-SMX can also produce a modest elevation in the plasma K concentration in non-HIV-infected subjects (14, 15). Hyperkalemia is thought to be caused by blocking of amiloride-sensitive Na channels in the collecting duct by TMP, which acts as a K-sparing diuretic (ll, 12, 16). If this is the case, hyponatremia would be inevitable, although there have been few reports of TMP-SMX-induced hyponatremia. Therefore, we consider that TMPcan cause both hyponatremia and hyperkalemia.
This study confirmed that TMP-SMX is implicated not only in hyperkalemia but also in hyponatremia. These electrolyte disorders were found in 14 of 53 patients (26.4%), which is more frequent than reported previously (7, 8) , The average dose of TMPwas 145.7±24.9 mg/day, which was not very high. Whenthe patients were monitored carefully, electrolyte disorders were seen even in the low-dose group. The incidence of electrolyte disorders increased with the dose of TMP. These results indicate that the incidence of hyponatremia and/or hyperkalemia is dependent on the dose of TMP.Multiple linear regression analysis revealed a significant correlation between changes in Na concentration and TMP-SMXis known to cause renal insufficiency (9, 20).
In this study, Cr levels were increased significantly in the high-dose TMP group. Electrolyte disorders were seen in 85.7% of patients with renal dysfunction compared with 17.5% of patients with normal renal function. As shown in Table 4 , multiple linear regression analysis showed no correlation between the change in Na concentration and the change in Cr concentration, whereas in the case of K, there was a significant correlation with the change in Cr concentration during TMPtreatment.
As almost all of the patients who were taking TMP-SMX had several underlying diseases and were being treated with many kinds of cytotoxic drugs or steroids, renal insufficiency was observed frequently, which increases the incidence of electrolyte disorders by TMP-SMX.Therefore, when TMPSMXis prescribed, electrolytes and serum Cr should be monitored closely even if the dose of TMP-SMXis low. Supplementation with Na and restriction of K intake are useful prophylactic measures. Although electrolyte disorders may nevertheless appear, they should be resolved after discontinuation of the treatment. Therefore, as long as electrolyte levels are monitored closely and prophylactic measures are implemented, TPM-SMX can be used safely. 
